Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb

 
• By Alaric DeArment

The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.

Novartis sold Xiidra and ophthalmology pipeline assets to Bausch + Lomb • Source: Shutterstock

More from Deals

More from Business